Germany-based Immatics (Nasdaq: IMTX), a company focused on the discovery and development of T cell-redirecting cancer immunotherapies, has entered into a license, development and commercialization agreement with US pharma major Bristol Myers Squibb (NYSE: BMY).
The agreement secures BMS a global exclusive license to Immatics’ TCR bispecific program, IMA401.
Following the announcement of the news, Immatics’ share price rose 5% in the first two hours of trading on Tuesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze